ArticleDiabetic medicine : a journal of the British Diabetic Association2026
Australian healthcare professionals' perspectives and experiences on screening and monitoring islet autoimmunity: A qualitative exploration.
Article in Diabetic medicine : a journal of the British Diabetic Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimsIslet autoantibodies characterise a period of immune-mediated destruction preceding clinical (symptomatic) type 1 diabetes. Screening and monitoring programmes for islet autoimmunity are being planned and implemented globally. The perspectives and experiences of healthcare professionals working in paediatric screening and monitoring of islet autoimmunity and clinical type 1 diabetes can inform these programmes.
methodsWe interviewed 32 healthcare professionals (81% women) caring for children with islet autoimmunity and/or clinical type 1 diabetes in Australia (median of 13 years of type 1 diabetes clinical experience). Data were analysed using reflexive thematic analysis.
resultsWe developed seven themes: 1. implementing population screening and monitoring is contested, 2. considerations for the structure of screening and monitoring, 3. prioritising equitable access and convenience, 4. focus on managing children's testing experiences, 5. potential psychological impacts of islet autoimmunity on children, 6. caregivers' perceived coping ability and associated responses to screening and monitoring and 7. importance of relationships with and support from healthcare professionals. Participants expressed benefits, concerns and considerations necessary for the well-organised, equitable and acceptable implementation of screening and monitoring. They described varying effects of testing and islet autoimmunity on families, emphasising the importance of trusted relationships between families and healthcare professionals.
conclusionsHealthcare professionals' insights can guide how screening and monitoring programmes are designed and implemented, particularly in justifying their introduction, ensuring equitable care and reducing adverse impacts on families. Further research will focus on the experiences of children and caregivers to integrate wider input into the design of these programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.